Long-term follow-up after bronchoscopic lung volume reduction treatment with coils in patients with severe emphysema
Jorine E Hartman, Karin Klooster, Kiki Gortzak, Nick H T ten Hacken, Dirk-Jan Slebos, Jorine E Hartman, Karin Klooster, Kiki Gortzak, Nick H T ten Hacken, Dirk-Jan Slebos
Abstract
Background and objective: Bronchoscopic lung volume reduction coil (LVR-coil) treatment has been shown to be safe and clinically effective in patients with severe emphysema in the short term; however, long-term safety and effectiveness has not been evaluated. The aim of this study was to investigate the long-term safety and effectiveness of LVR-coil treatment in patients with severe emphysema.
Methods: Thirty-eight patients with severe emphysema (median age is 59 years, forced expiratory volume in 1 s is 27% predicted) who were treated in LVR-coil clinical trials were invited for a voluntary annual visit. Safety was evaluated by chest X-ray and recording of adverse events and by efficacy by pulmonary function testing, 6-min walk distance (6MWD) and questionnaires.
Results: Thirty-five patients visited the hospital 1 year, 27 patients 2 years and 22 patients 3 years following coil placement. No coil migrations were observed on X-rays. At 1-year follow-up, all clinical outcomes significantly improved compared with baseline. At 2 years, residual volume % pred, modified Medical Research Council (mMRC) and the SGRQ score were still significantly improved. At 3 years, a significant improvement in mMRC score remained, with 40% of the patients reaching the 6MWD minimal important difference, and 59% for the St George's Respiratory Questionnaire (SGRQ) minimal important difference.
Conclusions: Follow-up of the patients treated with LVR-coils in our pilot studies showed that the coil treatment is safe with no late pneumothoraces, coil migrations or unexpected adverse events. Clinical benefit gradually declines over time; at 3 years post-treatment, around 50% of the patients maintained improvement in 6MWD, SGRQ and mMRC.
Clinical trial registration: NCT01220908 and NCT01328899 registered at ClinicalTrials.gov.
Keywords: bronchoscopy and interventional technique; clinical respiratory medicine; coil; emphysema; long-term follow-up.
© 2014 The Authors. Respirology published by Wiley Publishing Asia Pty Ltd on behalf of Asian Pacific Society of Respirology.
Figures
References
- Mineshita M, Slebos DJ. Bronchoscopic interventions for chronic obstructive pulmonary disease. Respirology. 2014;19:1126–1137.
- Herth FJ, Eberhardt R, Gompelmann D, Ficker JH, Wagner M, Ek L, Schmidt B, Slebos DJ. Radiological and clinical outcomes of using Chartis to plan endobronchial valve treatment. Eur. Respir. J. 2013;41:302–308.
- Shah PL, Herth FJ. Current status of bronchoscopic lung volume reduction with endobronchial valves. Thorax. 2014;69:280–286.
- Slebos DJ, Klooster K, Ernst A, Herth FJ, Kerstjens HA. Bronchoscopic lung volume reduction coil treatment of patients with severe heterogeneous emphysema. Chest. 2012;142:574–582.
- Shah P, Zoumot Z, Singh S, Bicknell SR, Ross ET, Quiring J, Hopkinson NS, Kemp SV RESET Trial Study Group. Endobronchial coils for the treatment of severe emphysema with hyperinflation (RESET): a randomised controlled trial. Lancet Respir. Med. 2013;1:233–240.
- Herth FJ, Eberhard R, Gompelmann D, Slebos DJ, Ernst A. Bronchoscopic lung volume reduction with a dedicated coil: a clinical pilot study. Ther. Adv. Respir. Dis. 2010;4:225–231.
- Deslee G, Klooster K, Hetzel M, Stanzel F, Kessler R, Marquette CH, Witt C, Blaas S, Gesierich W, Herth FJ, et al. Lung volume reduction coil treatment for patients with severe emphysema, a European multicenter feasibility trial. Thorax. 69:980–986.
- Klooster K, ten Hacken N, Franz I, Kerstjens HA, van Rixvoort EM, Slebos DJ. Lung volume reduction coil treatment in COPD patients with homogeneous emphysema: a prospective feasibility trial. Respiration. 2014;88:116–125. 2014.
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur. Respir. J. 2005;26:319–338.
- Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, et al. Standardisation of the measurement of lung volumes. Eur. Respir. J. 2005;26:511–522.
- Brooks D, Solway S, Gibbons WJ. ATS statement on six-minute walk test. Am. J. Respir. Crit. Care Med. 2003;167:1287.
- Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir. Med. 1991;85(Suppl. B):25–31. discussion 33–7.
- Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–586.
- Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111–124.
- Hartman JE, Ten Hacken NH, Klooster K, Boezen HM, de Greef MH, Slebos DJ. The minimal important difference for residual volume in patients with severe emphysema. Eur. Respir. J. 40:1137–1141.
- Puhan MA, Chandra D, Mosenifar Z, Ries A, Make B, Hansel NN, Wise RA, Sciurba F NETT Research Group. The minimal important difference of exercise tests in severe COPD. Eur. Respir. J. 2012;37:784–790. 2011.
- Jones PW. St: George's Respiratory Questionnaire. MCID. COPD. 2005;2:75–79.
- Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, Nordestgaard BG. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am. J. Respir. Crit. Care Med. 2012;186:975–981.
- Almagro P, Martinez-Camblor P, Soriano JB, Marin JM, Alfageme I, Casanova C, Esteban C, Soler-Cataluna JJ, de Torres JP, Celli BR, et al. Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study. PLoS ONE. 2014;9:e89866.
- Naunheim KS, Wood DE, Mohsenifar Z, Sternberg AL, Criner GJ, DeCamp MM, Deschamps CC, Martinez FJ, Sciurba FC, Tonascia J, et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann. Thorac. Surg. 2006;82:431–443.
- Gelb AF, McKenna RJ, Jr, Brenner M, Epstein JD, Zamel N. Lung function 5 yr after lung volume reduction surgery for emphysema. Am. J. Respir. Crit. Care Med. 2001;163:1562–1566.
- Travaline JM, Gaughan JP, Furukawa S, Criner GJ. Effect of bilateral lung volume reduction surgery on FEV1 decline in severe emphysema. COPD. 2005;2:203–208.
- Kramer MR, Refaely Y, Maimon N, Rosengarten D, Fruchter O. Two-year follow-up in patients treated with emphysematous lung sealant for advanced emphysema. Chest. 2013;144:1677–1680.
- Venuta F, Anile M, Diso D, Carillo C, De Giacomo T, Andrilli D, Fraioli F, Rendina EA, Coloni GF. Long-term follow-up after bronchoscopic lung volume reduction in patients with emphysema. Eur. Respir. J. 2012;39:1084–1089.
- Kotecha S, Westall GP, Holsworth L, Pham A, Williams TJ, Snell GI. Long-term outcomes from bronchoscopic lung volume reduction using a bronchial prosthesis. Respirology. 2011;16:167–173.
- Hopkinson NS, Kemp SV, Toma TP, Hansell DM, Geddes DM, Shah PL, Polkey MI. Atelectasis and survival after bronchoscopic lung volume reduction for COPD. Eur. Respir. J. 2011;37:1346–1351.
Source: PubMed